REPL Logo

Replimune Group, Inc. (REPL) 

NASDAQ
Market Cap
$757.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
689 of 774
Rank in Industry
376 of 432

Largest Insider Buys in Sector

REPL Stock Price History Chart

REPL Stock Performance

About Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing …

Insider Activity of Replimune Group, Inc.

Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $978,943 worth of Replimune Group, Inc. stock.

On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $0 and sold $16M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.

List of Insider Buy and Sell Transactions, Replimune Group, Inc.

2024-11-18SaleChief Medical Officer
7,246
0.0106%
$10.78$78,1120.00%
2024-11-18SaleChief Commercial Officer
5,207
0.0076%
$10.78$56,1310.00%
2024-08-16SaleChief Financial Officer
8,938
0.0137%
$10.18$90,9890.00%
2024-06-07SaleChief Medical Officer
15,881
0.0245%
$7.50$119,108+33.35%
2024-05-16Saledirector
11,464
0.0189%
$6.47$74,172+53.64%
2024-05-16SaleExecutive Chairman
37,928
0.0626%
$6.47$245,394+53.64%
2024-05-16SaleChief Operating Officer
17,615
0.0291%
$6.47$113,969+53.64%
2024-05-16SaleChief Executive Officer
20,194
0.0333%
$6.47$130,655+53.64%
2024-05-16SaleChief Medical Officer
6,367
0.0105%
$6.47$41,194+53.64%
2024-05-16SaleChief Commercial Officer
2,218
0.0037%
$6.47$14,350+53.64%
2024-05-16SaleChief Accounting Officer
2,298
0.0038%
$6.47$14,868+53.64%
2023-11-16SaleChief Medical Officer
7,313
0.0131%
$10.92$79,858-17.07%
2023-11-16SaleChief Commercial Officer
5,255
0.0094%
$10.92$57,385-17.07%
2023-09-12SaleChief Business Officer
300
0.0005%
$20.00$6,000-55.11%
2023-09-11SaleChief Business Officer
5,358
0.0092%
$20.01$107,214-56.49%
2023-08-22SaleChief Business Officer
18,600
0.0315%
$20.01$372,186-56.96%
2023-08-11SaleChief Business Officer
1,400
0.0024%
$20.00$28,000-56.52%
2023-07-10SaleChief Business Officer
20,000
0.035%
$21.58$431,541-58.52%
2023-06-13SaleChief Strategy Officer
5,698
0.0098%
$24.05$137,008-62.70%
2023-06-13SaleChief Dev. Op. Officer
12,860
0.0221%
$24.06$309,395-62.70%

Insider Historical Profitability

12.92%
Omega Fund IV, L.P.
4763380
6.9622%
$11.07220+27.98%
Slootweg Hugo Alexander
4721449
6.9009%
$11.0710<0.0001%
Forbion Capital Fund III Cooperatief U.A.10 percent owner
4721449
6.9009%
$11.0710<0.0001%
Bain Capital Life Sciences Investors, LLC10 percent owner
2838968
4.1495%
$11.0710<0.0001%
Rhodes Jason Pdirector
946000
1.3827%
$11.07111+63.12%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$77.99M14.239.55M0%+$00.56
T. Rowe Price$53.51M9.766.55M+11.96%+$5.72M0.01
State Street$53M9.676.49M+26.9%+$11.24M<0.01
BlackRock$37.68M6.884.61M+1.63%+$605,160.07<0.01
Redmile Group$30.47M5.563.73M-3.5%-$1.11M0.31
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.